Ludmila Lozneanu1, Patrizia Pinciroli2, Delia Apostol Ciobanu3, Maria Luisa Carcangiu4, Silvana Canevari2, Antonella Tomassetti2, Irina-Draga Căruntu5. 1. Department of Morphofunctional Sciences - Histology, Pathology, "Grigore T. Popa" University of Medicine and Pharmacy, Iassy, Romania Department of Experimental Oncology and Molecular Medicine - Unit of Molecular Therapies, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 2. Department of Experimental Oncology and Molecular Medicine - Unit of Molecular Therapies, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 3. Department of Morphofunctional Sciences - Histology, Pathology, "Grigore T. Popa" University of Medicine and Pharmacy, Iassy, Romania Department of Pathology - "Sf. Spiridon" University Hospital, Iassy, Romania. 4. Department of Anatomic Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Department of Morphofunctional Sciences - Histology, Pathology, "Grigore T. Popa" University of Medicine and Pharmacy, Iassy, Romania irinadragacaruntu@gmail.com.
Abstract
BACKGROUND/AIM: The activation of the membrane tyrosine kinase AXL is implicated in the migration and invasion in several carcinomas, including ovarian cancer. Herein, we investigated the association of the expression of AXL transcript and protein to the aggressiveness of ovarian cancer, as well as to patient outcome. MATERIALS AND METHODS: Overall and relapse-free survival were determined with respect to AXL transcript levels by computational analysis on two publicly available datasets containing data of gene expression from high-grade ovarian cancers (n=776). Immunohistochemical evaluation of AXL protein expression was then performed using a proprietary tissue microarray consisting of 62 ovarian cancers of different histology, grading and staging. Expression was analyzed for association with clinicopathological parameters, including survival. RESULTS: In both analyzed datasets, AXL transcript expression was significantly associated to both overall and relapse-free survival in high-grade ovarian cancers. Membrane expression of AXL protein was observed in 89% of the analyzed ovarian cancers. A significant correlation was found between AXL expression and serous histologic subtype, higher tumor grade and type II tumors. No significant association between AXL protein expression and patient survival was found in our cohort. AXL is frequently expressed in high-grade serous ovarian cancers and its expression is significantly associated to tumors displaying poor prognosis. CONCLUSION: AXL is a potential prognostic marker for the most aggressive ovarian carcinomas. Copyright
BACKGROUND/AIM: The activation of the membrane tyrosine kinase AXL is implicated in the migration and invasion in several carcinomas, including ovarian cancer. Herein, we investigated the association of the expression of AXL transcript and protein to the aggressiveness of ovarian cancer, as well as to patient outcome. MATERIALS AND METHODS: Overall and relapse-free survival were determined with respect to AXL transcript levels by computational analysis on two publicly available datasets containing data of gene expression from high-grade ovarian cancers (n=776). Immunohistochemical evaluation of AXL protein expression was then performed using a proprietary tissue microarray consisting of 62 ovarian cancers of different histology, grading and staging. Expression was analyzed for association with clinicopathological parameters, including survival. RESULTS: In both analyzed datasets, AXL transcript expression was significantly associated to both overall and relapse-free survival in high-grade ovarian cancers. Membrane expression of AXL protein was observed in 89% of the analyzed ovarian cancers. A significant correlation was found between AXL expression and serous histologic subtype, higher tumor grade and type II tumors. No significant association between AXL protein expression and patient survival was found in our cohort. AXL is frequently expressed in high-grade serous ovarian cancers and its expression is significantly associated to tumors displaying poor prognosis. CONCLUSION:AXL is a potential prognostic marker for the most aggressive ovarian carcinomas. Copyright
Authors: Mary M Mullen; Elena Lomonosova; Michael D Toboni; Alyssa Oplt; Emily Cybulla; Barbara Blachut; Peinan Zhao; Hollie Noia; Daniel Wilke; Erinn B Rankin; Lindsay M Kuroki; Andrea R Hagemann; Ian S Hagemann; Carolyn K McCourt; Premal H Thaker; David G Mutch; Matthew A Powell; Nima Mosammaparast; Alessandro Vindigni; Katherine C Fuh Journal: Mol Cancer Res Date: 2021-10-20 Impact factor: 6.333
Authors: Ling Rao; Victor C Y Mak; Yuan Zhou; Dong Zhang; Xinran Li; Chloe C Y Fung; Rakesh Sharma; Chao Gu; Yiling Lu; George L Tipoe; Annie N Y Cheung; Gordon B Mills; Lydia W T Cheung Journal: Nat Commun Date: 2020-05-08 Impact factor: 14.919
Authors: Marie-Anne Goyette; Islam E Elkholi; Chloé Apcher; Hellen Kuasne; Carla V Rothlin; William J Muller; Darren E Richard; Morag Park; Jean-Philippe Gratton; Jean-François Côté Journal: Proc Natl Acad Sci U S A Date: 2021-07-20 Impact factor: 11.205